Detalhe da pesquisa
1.
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
Clin Gastroenterol Hepatol
; 21(1): 182-191.e2, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644343
2.
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Dig Dis Sci
; 68(6): 2647-2657, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920666
3.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
N Engl J Med
; 382(1): 92, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31875506
4.
Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
Am J Gastroenterol
; 113(3): 384-395, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29317770
5.
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
Aliment Pharmacol Ther
; 57(1): 117-126, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282200
6.
Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
J Crohns Colitis
; 15(11): 1920-1930, 2021 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909062
7.
A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.
Aliment Pharmacol Ther
; 51(11): 1076-1086, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32339331
8.
Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
Aliment Pharmacol Ther
; 52(8): 1366-1376, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32901983
9.
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Aliment Pharmacol Ther
; 52(1): 123-134, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32441396
10.
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
J Crohns Colitis
; 14(1): 33-45, 2020 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31219157
11.
Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab.
Clin Pharmacol Ther
; 107(5): 1189-1199, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31677154
12.
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Aliment Pharmacol Ther
; 51(9): 880-888, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32237087
13.
Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
Aliment Pharmacol Ther
; 54(4): 534-535, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34331810
14.
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
Aliment Pharmacol Ther
; 52(7): 1255-1256, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33016547
15.
Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
Aliment Pharmacol Ther
; 52(4): 753-754, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32886363
16.
Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.
Aliment Pharmacol Ther
; 52(10): 1617-1618, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33085982